Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review.

Autor: O Murchu E; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland.; The Centre for Health Policy and Management, Trinity College Dublin, Dublin 2, Ireland., Byrne P; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., Walsh KA; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., Carty PG; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., Connolly M; School of Medicine, National University of Ireland Galway, Galway, Ireland., De Gascun C; UCD National Virus Reference Laboratory, University College Dublin, Dublin 4, Ireland., Jordan K; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., Keoghan M; Department of Clinical Immunology, Beaumont Hospital, Dublin 9, Ireland., O'Brien KK; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., O'Neill M; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., Smith SM; Department of General Practice, Health Research Board Centre for Primary Care Research, Royal College of Surgeons in Ireland, Dublin 2, Ireland., Teljeur C; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland., Ryan M; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland.; Department of Pharmacology & Therapeutics, Trinity Health Sciences, Trinity College Dublin, Dublin 8, Ireland., Harrington P; Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin 7, Ireland.
Jazyk: angličtina
Zdroj: Reviews in medical virology [Rev Med Virol] 2021 Mar; Vol. 31 (2), pp. e2162. Date of Electronic Publication: 2020 Sep 23.
DOI: 10.1002/rmv.2162
Abstrakt: In this review, we systematically searched and summarized the evidence on the immune response and reinfection rate following SARS-CoV-2 infection. We also retrieved studies on SARS-CoV and MERS-CoV to assess the long-term duration of antibody responses. A protocol based on Cochrane rapid review methodology was adhered to and databases were searched from 1/1/2000 until 26/5/2020. Of 4744 citations retrieved, 102 studies met our inclusion criteria. Seventy-four studies were retrieved on SARS-CoV-2. While the rate and timing of IgM and IgG seroconversion were inconsistent across studies, most seroconverted for IgG within 2 weeks and 100% (N = 62) within 4 weeks. IgG was still detected at the end of follow-up (49-65 days) in all patients (N = 24). Neutralizing antibodies were detected in 92%-100% of patients (up to 53 days). It is not clear if reinfection with SARS-CoV-2 is possible, with studies more suggestive of intermittent detection of residual RNA. Twenty-five studies were retrieved on SARS-CoV. In general, SARS-CoV-specific IgG was maintained for 1-2 years post-infection and declined thereafter, although one study detected IgG up to 12 years post-infection. Neutralizing antibodies were detected up to 17 years in another study. Three studies on MERS-CoV reported that IgG may be detected up to 2 years. In conclusion, limited early data suggest that most patients seroconvert for SARS-CoV-2-specific IgG within 2 weeks. While the long-term duration of antibody responses is unknown, evidence from SARS-CoV studies suggest SARS-CoV-specific IgG is sustained for 1-2 years and declines thereafter.
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: